Plus Therapeutics, Inc. (NASDAQ:PSTV) Q4 2023 Earnings Call Transcript
Plus Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.7, expectations were $-0.78.
No. | Hedge Fund | Shares | Value | Activity | % Port |
---|---|---|---|---|---|
1. | Citadel Investment Group Ken Griffin | 0 | $0 | -100% | 0% |
2. | Renaissance Technologies Jim Simons | 0 | $0 | -100% | 0% |
Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
---|---|---|---|---|---|---|
$1.95 | 1,000 | Director | 25,160 | 2023-11-16 | Filing | |
$1.77 | 1,000 | Director | 24,160 | 2023-11-15 | Filing | |
$1.43 | 4,000 | Director | 23,160 | 2023-11-13 | Filing | |
$1.45 | 2,000 | Director | 19,160 | 2023-11-10 | Filing | |
$1.59 | 4,199 | Director | 17,160 | 2023-11-09 | Filing |
Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
---|---|---|---|---|---|---|
$1.96 | 2,068 | Officer, Director | 170 | 2023-11-20 | Filing | |
$0.31 | 1,500 | Director | 8,500 | 2022-12-30 | Filing | |
$0.34 | 473,831 | Large Shareholder | 4,543,086 | 2018-02-14 | Filing | |
$0.31 | 101,710 | Large Shareholder | 5,016,917 | 2018-02-13 | Filing | |
$0.31 | 185,272 | Large Shareholder | 5,118,627 | 2018-02-12 | Filing |